Vantage logo

Ovid joins the rare epilepsy race

Ovid Therapeutics gets a mid-stage win in Dravet syndrome, but might have a hard time going up against Zogenix’s Fintepla.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.